ClinicalTrials.gg
WithdrawnNCT03422419PROGRESSUpdated Nov 1, 2018

TIPS or Anticoagulation in Portal Vein Thrombosis

A Phase 3 interventional study of Heparin and TIPS in Thrombosis Portal Vein, sponsored by Insel Gruppe AG, University Hospital Bern. Withdrawn. Per ClinicalTrials.gov, last updated 2018-11-01.

Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
lack of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Sex
All
01

Study summary

The PROGRESS is an investigator-initiated, multicentre, randomized, trial comparing anticoagulation, which is the currently most frequently used treatment, alone, versus transjugular intrahepatic portosystemic shunt (TIPS) combined with anticoagulation, in patients presenting with recent obstructive portal vein thrombosis (ROPVT). The rationale of this study is to significantly increase the proportion of patients that achieve a complete or partial recanalization of the portal vein. The intervention of this study consists in TIPS deployment and catheter based clot removal in addition to anticoagulation. The investigators retain that this intervention will increase the proportion of patients with an open portal vein from 38% with anticoagulation alone to 83% with anticoagulation and TIPS after 6 months. Both anticoagulant therapy and clot removal/TIPS are treatments that are currently available and accepted indications for the treatment of ROPVT. Anticoagulation will be performed with unfractioned heparin or low molecular weight heparin initially and with vitamin K antagonists in the long term. The investigators plan to collect blood for biobanking at the time of inclusion and after 6 months. Blood samples for a biobank will be collected.

02

Conditions studied

  • Thrombosis Portal Vein
03

In context

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 742 studies on the registry; 180 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Recent complete thrombosis of the extrahepatic portal vein either with or without the involvement of intrahepatic branches and with or without involvement of splenic vein and superior mesenteric vein
  2. Written

Exclusion criteria

Exclusion Criteria:

  1. Malignant Portal Vein thrombosis (neoplastic invasion)
  2. Intraabdominal
  3. Chronic diseases limiting in the short term (6 months)
  4. Liver transplantation
  5. Unwillingness to participate
  6. to TIPS (including past or present hepatic encephalopathy Grade ≥2)
  7. -Turcotte score 11 or more points in patients with advanced chronic liver disease-
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TIPS+Anticoagulation

    Drug: Heparin · Device: TIPS

  • Active comparator
    Anticoagulation

    Drug: Heparin

Interventions

  • The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.

  • DeviceTIPS

    transjugular intrahepatic portosystemic shunt deployment

06

What researchers measure

Primary outcomes

  1. Proportion of patients with complete recanalization of the portal vein".

    Time frame: 6 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2018; primary completion for Oct 2020, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 5, 2018
StartEst.
Aug 1, 2018
Primary completionEst.
Oct 31, 2020
CompletionEst.
Jul 31, 2021
Last update
Nov 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03422419
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Aug 1, 2018 (estimated)
Primary completion
Oct 31, 2020 (estimated)
Completion
Jul 31, 2021 (estimated)
Last update
Nov 1, 2018

Study contacts

Andrea De Gottardi, Prof. Dr. med
principal investigator · Insel Gruppe AG, University Hospital Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion